source
- STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data neededEli Lilly's deal with Profluent, Erasca's RAS-targeting cancer pill, and more biotech news todaySTAT · 3mo ago↗ source
- STAT+: Google’s clinical director on AI challengesIn this edition of STAT Health Tech newsletter: a conversation with Google's clinical director, an update on Doctronic's Utah experiment, and more.STAT · 3mo ago↗ source
- Updated: AbbVie flirts with popular pan-RAS field in up to $1.45B option to acquire KestrelThe pan-RAS space continues to gain momentum, as AbbVie signs up for a shot at entering a field with the potential to drastically alter the treatment of certain cancers. The Chicago-area pharma gia…Endpoints · 3mo ago